What's Happening?
The Food and Drug Administration (FDA) has classified the spinal imaging system for neuraxial procedures into Class II (special controls). This decision was made following a request from IntuiTap Medical, Inc. for De Novo classification of its VerTouch
Spinal Imaging Device. The FDA determined that classifying the device into Class II, with the establishment of special controls, provides reasonable assurance of its safety and effectiveness. This action is intended to enhance patient access to beneficial innovative devices by reducing regulatory burdens, as it places the device in a lower device class than the automatic Class III assignment. The FDA issued an order to the requester on January 19, 2024, and is now codifying this classification by adding 21 CFR 868.1985 to its regulations. The generic device type is identified as a sensor and software system used to assist in identifying the interspinous space for neuraxial procedures.
Why It's Important?
This classification by the FDA is significant for the medical device industry and healthcare providers in the U.S. By classifying the spinal imaging system as Class II, the FDA aims to streamline the regulatory pathway for similar innovative devices. This can lead to faster market entry for new technologies that assist in neuraxial procedures, potentially improving patient care and outcomes. The establishment of special controls, which include clinical performance testing, non-clinical performance testing, human factors testing, software verification and validation, electrical safety testing, biocompatibility evaluation, and sterilization validation, ensures that these devices meet rigorous safety and effectiveness standards. This regulatory clarity benefits manufacturers by providing a defined path for compliance and reduces the burden of the more stringent Class III premarket approval process, fostering innovation in spinal imaging technology.
What's Next?
Following this classification, manufacturers of spinal imaging systems for neuraxial procedures will need to comply with the specified special controls to market their devices in the U.S. The device is subject to premarket notification requirements under section 510(k) of the FD&C Act, meaning manufacturers will need to demonstrate substantial equivalence to a predicate device or follow the De Novo pathway if no predicate exists. This regulatory framework will likely encourage further development and adoption of these technologies in clinical settings. The FDA's decision also sets a precedent for future classifications of similar devices, potentially influencing research and development efforts in the medical imaging sector. The agency will continue to oversee the safety and effectiveness of these devices through post-market surveillance and compliance with the established controls.
Beyond the Headlines
The FDA's approach to classifying this spinal imaging system highlights a broader trend in medical device regulation: balancing innovation with patient safety. By utilizing the De Novo classification process, the FDA can create a new regulatory classification for novel devices that do not have a predicate, thereby facilitating their market entry while still ensuring appropriate oversight. This move could encourage investment in medical technology startups and research, particularly in areas where existing diagnostic or procedural tools are suboptimal. The emphasis on human factors testing and software validation also underscores the increasing complexity of modern medical devices, where user interface and software integrity are critical for safe and effective operation. This classification could also lead to a re-evaluation of existing neuraxial procedure techniques, potentially shifting clinical practices towards more image-guided approaches.
